NeuroproteXeon is a late clinical-stage pharmaceutical company developing the proprietary use of xenon gas, delivered via a patented inhalation device, to protect against brain cell death following acute neurologic injury. NP is currently preparing for a Phase III Clinical Trial in Out of Hospital Cardiac Arrest (OHCA).
Looking for a particular NeuroproteXeon employee's phone or email?
The NeuroproteXeon annual revenue was $3 million in 2026.
1 people are employed at NeuroproteXeon.
NeuroproteXeon is based in Orchard Park, New York.
The NAICS codes for NeuroproteXeon are [325, 32, 3254, 32541].
The SIC codes for NeuroproteXeon are [28, 283].